Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cells counts in resource-limited settings

Current HIV Research

Volumn 6, Issue 1, 2008, Pages 65-69

  Kiertiburanakul, Sasisopin ^a   Sungkanuparph, Somnuek ^a   Charoenyingwattana, Angkana ^b   Mahasirimongkol, Surakameth ^c   Sura, Thanyachai ^a   Chantratita, Wasun ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c MINISTRY OF PUBLIC HEALTH   (Thailand)

Author keywords

AIDS; HIV; Nevirapine; Rash; Resource limited settings; Risk factor

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; COTRIMOXAZOLE; DAPSONE; EFAVIRENZ; FLUCONAZOLE; GPO VIR; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANAMNESIS; BODY WEIGHT; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CRYPTOCOCCOSIS; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTIS PNEUMONIA; REVIEW; RISK FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS; ARTICLE; CHEMICALLY INDUCED DISORDER; DEVELOPING COUNTRY; KAPLAN MEIER METHOD; RASH;

ADULT; BODY WEIGHT; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; DEVELOPING COUNTRIES; DRUG HYPERSENSITIVITY; EXANTHEMA; FEMALE; HIV INFECTIONS; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS;

EID: 40449096002     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016208783571946     Document Type: Review

References (22)

1. DHHS. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents; Version October 10, 2006. Cited June 20, 2007. Available from URL http://aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf.
2. Cohen J. Thailand's do-it-yourself therapy. Science 2003; 301: 1662.
3. Viramune package insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc, January 2004.
4. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356: 1423-1430.
5. Montessori V, Press N, Harris M, Akagi L, Montaner JS. Adverse effects of antiretroviral therapy for HIV infection. CMAJ 2004; 170: 229-238.
6. Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 1998; 20: 1071-1092.
7. Metry DW, Lahart CJ, Farmer KL, Hebert AA. Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine. J Am Acad Dermatol 2001; 44: 354-357.
8. Ananworanich J, Moor Z, Siangphoe U, et al. Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. AIDS 2005; 19: 185-192.
9. van Leth F, Andrews S, Grinsztejn B, et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or favirenz-based first-line HAART. AIDS 2005; 19: 463-471.
10. de Maat MM, ter Heine R, Mulder JW, et al. Incidence and risk factors for nevirapine-associated rash. Eur J Clin Pharmacol 2003; 59: 457-462.
11. Antinori A, Baldini F, Girardi E, et al. Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. AIDS 2001; 15: 1579-1581.
12. Division of AIDS table for grading the severity of adult and pediatric adverse events. Public date: December, 2004. Cited July 1, 2007. Available from URL http://www3.niaid.nih.gov/research/resources/ DAIDSClinRsrch/PDF/Safety/DAIDSAEGradingTable.pdf.
13. Knobel H, Miro JM, Domingo P, et al. Failure of a short-term prednisone regimen to prevent nevirapine-associated rash: a double-blind placebo-controlled trial: the GESIDA 09/99 study. J Acquir Immune Defic Syndr 2001; 28: 14-18.
14. Anekthananon T, Ratanasuwan W, Techasathit W, Sonjai A, Suwanagool S. Safety and efficacy of a simplified fixed-dose combination of stavudine lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study. J Med Assoc Thai 2004; 87: 760-767.
15. Getahun A, Tansuphasawadikul S, Desakorn V, Dhitavat J, Pitisuttithum P. Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapina (GPO-vir) in advanced HIV infection. J Med Assoc Thai 2006; 89: 1472-1478.
16. Kiertiburanakul S, Khongnorasat S, Rattanasiri S, Sungkanuparph S. Efficacy of a generic filed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) in Thai HIV-infected patients. J Med Assoc Thai 2007; 90: 237-243.
17. Barreiro P, Soriano V, Casas E, et al. Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. AIDS 2000; 14: 2153-2157.
18. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, Naldi L, Viboud C, Roujeau JC. Nevirapine and the risk of Stevens-Johson syndrome or toxic epidermal necrolysis. AIDS 2001; 15: 1843-1848.
19. Winston A, Pozniak A, Smith N, et al. Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals? AIDS 2004; 18: 572-574.
20. Montaner JS, Cahn P, Zala C, et al. Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. J Acquir Immune Defic Syndr 2003; 33: 41-46.
21. Bersoff-Matcha SJ, Miller WC, Aberg JA, et al. Sex differences in nevirapine rash. Clin Infect Dis 2001; 32: 124-129.
22. Launay O, Roudiere L, Boukli N, et al. Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: results of the viramune-zyrtec double-blind, placebo-controlled trial. Clin Infect Dis 2604; 38: e66-72.